REG - Oxford Biomedica PLC - Board Appointment

Oxford BioMedicaAnnouncement

26/04/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230426:nRSZ4527Xa&default-theme=true

RNS Number : 4527X  Oxford Biomedica PLC  26 April 2023

 

Oxford Biomedica Appoints Leone Patterson as Non-Executive Director

 

Oxford, UK - 26(th) April 2023: Oxford Biomedica plc (LSE:OXB) ("Oxford
Biomedica" or "the Company"), a quality and innovation-led viral vector CDMO,
today announces the appointment of Ms Leone Patterson as an Independent
Non-Executive Director. Ms Patterson shall join the Board on 1(st) May 2023.

 

Ms Patterson has more than 20 years of public company biotech experience
including in the cell and gene therapy industry and has managed significant
growth within international commercial companies working across areas
including strategy, finance, operations and governance.

 

She is currently the Chief Financial and Business Officer at Tenaya
Therapeutics (NASDAQ: TNYA), a clinical-stage company with a mission to
discover, develop, and deliver potentially curative therapies, including gene
therapy, for heart disease. Ms Patterson also serves on the Board of Directors
for Nkarta (NASDAQ:NKTX), a clinical-stage cell therapy company. Previously,
Ms Patterson held leadership roles, including Chief Executive Officer and
Chief Financial Officer, at Adverum Biotechnologies, a gene therapy company
focused on rare and ocular diseases. She has also held the role of Chief
Financial Officer at public companies, including diagnostics firm Diadexus and
speciality pharmaceuticals provider Transcept Pharmaceuticals and, earlier in
her career, worked within Novartis, Chiron and KPMG. She holds a B.S. in
business administration and accounting from Chapman University, an executive
M.B.A. from St. Mary's College, and is a Certified Public Accountant
(inactive).

 

Dr. Roch Doliveux, Chair of Oxford Biomedica, said: "The appointment of Leone
comes at an important juncture for Oxford Biomedica, as we advance our global
leadership in viral vector development and supply, providing innovative
solutions to our international biopharma customers. Leone's deep understanding
of corporate finance, her experience of the US public markets and M&A, in
addition to her extensive experience in the cell and gene therapy industry
will be invaluable in supporting our international strategy and further
strengthening our market position."

 

 Ms Leone Patterson said: "I am honoured to be joining the Board of Oxford
Biomedica, a global innovation-led CDMO dedicated to enabling the development
of life-saving cell and gene therapies. I look forward to working with the
Board and contributing my expertise to help advance the Company's strategy."

 

Diadexus voluntarily filed for Chapter 7 bankruptcy in June 2016 while Ms.
Patterson was its Chief Financial Officer. Save as disclosed, there are no
other disclosures required to be made in accordance with LR 9.6.13R.

 

-Ends-

 

Enquiries:

 

 

Oxford Biomedica plc:

 

Taylor Boyd, VP, Head of IR - T: +1 (984) 268 8488/ E: ir@oxb.com

Sophia Bolhassan, VP, Corporate Affairs and IR - T: +44 (0) 7394 562 425 / E:
ir@oxb.com

 

Consilium Strategic Communications:

T: +44 (0)20 3709 5700 / E: oxfordbiomedica@consilium-comms.com

 

Mary-Jane Elliott / Matthew Neal / Davide Salvi

 

 

About Oxford Biomedica

 

Oxford Biomedica (LSE: OXB) is a quality and innovation-led viral vector CDMO
with a mission to enable its clients to deliver life changing therapies to
patients around the world.

 

One of the original pioneers in cell and gene therapy, the Company has more
than 25 years of experience in viral vectors; the driving force behind the
majority of gene therapies. The Company collaborates with some of the world's
most innovative pharmaceutical and biotechnology companies, providing viral
vector development and manufacturing expertise in lentivirus, adeno-associated
virus (AAV) and adenoviral vectors. Oxford Biomedica's world-class
capabilities span from early-stage development to commercialisation. These
capabilities are supported by robust quality-assurance systems, analytical
methods and depth of regulatory expertise.

 

Oxford Biomedica, a FTSE4Good constituent, is headquartered in Oxford, UK. It
has locations across Oxfordshire, UK and a US-based subsidiary, Oxford
Biomedica Solutions, based near Boston, MA, US. Learn more at www.oxb.com,
www.oxbsolutions.com, and follow us on LinkedIn, Twitter and YouTube.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOAPPUAGCUPWPGA